Syntax Advisors, LLC Vertex Pharmaceuticals Inc Transaction History
Syntax Advisors, LLC
- $57.7 Million
- Q3 2023
A detailed history of Syntax Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Syntax Advisors, LLC holds 678 shares of VRTX stock, worth $318,144. This represents 0.41% of its overall portfolio holdings.
Number of Shares
678
Previous 690
1.74%
Holding current value
$318,144
Previous $242,000
2.89%
% of portfolio
0.41%
Previous 0.37%
Shares
8 transactions
Others Institutions Holding VRTX
# of Institutions
1,725Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.6 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.9 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.54 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.22 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...